Drug Trial Radar · NCT05421013
Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
9
Actual
Start
Aug 1, 2022
Primary completion
Mar 29, 2023
Study completion Mar 29, 2023
Sponsor
- Lead sponsor
- SirnaomicsIndustry
- Sponsor type
- Industry
- First posted
- Jun 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open label, dose escalation to evaluate safety.
Conditions
- Facial isSCC
Interventions
STP705Drug
STP705 targets TGFB-1 and COX-2 mRNA respectively.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants With Histological Clerance of Treated isSCC Lesion at the End of TreatmentTime frame: 21 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center for Clinical and Cosmetic Research
Aventura, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.